Temperature Excursion Risk Window in Pharmaceutical Air Cargo

Abstract Purpose This paper challenges the prevailing flight-phase bias in pharmaceutical air cargo cold chain research by identifying the ground transfer dwell period — between aircraft offload and temperature-controlled facility re-entry — as the primary and systemically undermonitored thermal risk window in international pharmaceutical shipments. Design/Methodology/Approach: A practitioner observation methodology is applied across three professional lenses spanning 19 years of multi-carrier air cargo experience: airfreight operations at DHL, commercial pricing at DB Schenker, and route-level data analytics at Turkish Airlines Cargo. Secondary analysis incorporates IATA, FDA, and carrier performance datasets. Findings: Ground transfer events — unscheduled apron dwell, non-conditioned pre-departure staging, and customs clearance dwell at U.S. ports of entry — account for a disproportionate share of temperature excursion events in multi-leg pharmaceutical shipments. A commercial pricing mechanism, documented from DB Schenker pricing executive experience, incentivises multi-stop routing that systematically multiplies ground transfer exposure. The South Asia pharmaceutical corridor, characterised by FDA import alert risk and Gulf hub routing, presents the most thermally vulnerable supply chain profile in the global air cargo network. Practical Implications: Carrier-agnostic, integrated monitoring platforms that connect predictive delay intelligence with container thermal tolerance calculations represent the necessary evolution beyond flight-phase-centric cold chain management. Originality/Value: This paper provides the first practitioner-grounded identification of ground transfer dwell time as the dominant pharmaceutical cold chain failure window, combining operational observation, commercial pricing intelligence, and data analytics in a methodology not replicable from secondary sources.